Skip to main content

Cell death and immune regulation: in vivo application of a novel agonistic monoclonal antibody for death receptor Fas

Fas (CD95/Apo-1) is a cell surface death receptor belonging to the tumor necrosis factor receptor super family. Fas can transduce an apoptosis-inducing signal in cells when stimulated by Fas ligand (FasL) or by agonistic anti-Fas monoclonal antibodies. Mice with Fas-defective lymphoproliferation and with FasL-defective generalized lymphoproliferative disease (gld) mutations develop autoimmune disease and lymphoadenopathy, indicating that the death receptor Fas is a functional molecule in eliminating either autoreactive peripheral T lymphocytes and B lymphocytes or tumor cells. On the contrary, Fas has been also regarded to work as an inducer of tissue damage in fulminant hepatitis, graft-versus-host disease and tissue-specific autoimmune disease. In vivo stimulation of Fas by administration of different agonistic anti-mouse Fas monoclonal antibodies (mAbs) also induces opposite biological effects in mice. Administration of antimouse Fas mAb Jo2 killed mice within 5 hours by causing fulminant hepatitis with hemorrhage, while administration of antimouse Fas mAb RK8 to FasL-deficient MRL-gld/gld mice, which never kills mice, not only reduced the autoimmune symptoms including nephritis, arthritis and vasculitis, but also reduced lymphoadenopathy.

I shall propose a strategy for therapeutic use of a novel agonistic anti-Fas monoclonal antibody HFE-7A for autoimmune disease including rheumatoid arthritis and other diseases including cancer. Antihuman Fas mAb HFE7A, which cross-reacts with Fas of various mammals, ranging from humans to mice, can induce apoptosis in vitro both in human and mouse Fas-expressing T-cell lines. Moreover, HFE7A shows very interesting in vivo effects of inducing Fas-mediated apoptosis in lymphocytes including mouse thymocytes and abnormal gld T cells and for inhibiting Fas-mediated fulminant hepatitis induced by Jo2. Not only mice, but also monkeys given a high dose of HFE7A never showed liver injury. In vivo therapeutic effects of humanized anti-Fas mAb HFE7A against human rheumatoid arthritis and human adult T-cell leukemia in SCID mice will be also summarized.

Author information

Affiliations

Authors

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yonehara, S. Cell death and immune regulation: in vivo application of a novel agonistic monoclonal antibody for death receptor Fas. Arthritis Res Ther 5, 108 (2003). https://doi.org/10.1186/ar909

Download citation

Keywords

  • Tumor Necrosis Factor Receptor
  • Fulminant Hepatitis
  • Human Rheumatoid Arthritis
  • Mouse Thymocyte
  • Cell Surface Death Receptor